$RKLB

Klein Frank sold $2.4M of RKLB

Klein Frank (Chief Operations Officer) sold 35,558 shares of Rocket Lab Corp (RKLB) at an average of $66.61 ($66.25–$67.54, $2.37M total) across 3 trades on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Klein Frank
Published Aug 28, 2026, 10:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RKLB
Bearish
medium confidence
Mentioned
$RKLB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RKLBBearishLow
01

Why it matters

The Form 4 filing provides the first public disclosure of this insider sale, offering a fresh data point for traders.

02

Market read

Primary insider sale; modest negative signal for RKLB but limited broader market impact.

03

What to watch

10b5‑1 plans are pre‑scheduled; the sale may have been planned before any material news.

Relevance 5/10Novelty 5/10Timing: filed 2026‑08‑28, effective immediately

Background

Rocket Lab (RKLB) is a small‑cap space launch provider; recent earnings showed growth, but no major news today.

Company-level read

Ticker impact

$RKLBBearishMedium confidence
Context

COO Klein Frank sold 35,558 shares for $2.37M via a 10b5‑1 plan, reducing his stake to 925,737 shares.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

Sale size is modest relative to float; typical for 10b5‑1 plans, but still a fresh negative data point.

Market effects

Limited impact on aerospace/space launch sector; similar insider sales have minimal sector ripple.

US market only, no broader regional effect.

Low global relevance.

Counterpoint

Insider may be diversifying; sale does not necessarily indicate negative outlook for Rocket Lab.

Key entities

  • Klein Frank

    Chief Operations Officer of Rocket Lab

  • Rocket Lab Corp

    US‑listed aerospace company (ticker RKLB)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RKLBHigh

Rocket Lab (RKLB) Stock Drops After Neutron Rocket Launch Delay

Rocket Lab (RKLB) shares fell 7.9% during trading and 7.3% after-hours after delaying its Neutron rocket launch to 2027 due to manufacturing issues. The company's P/S ratio is 45.17, above historical and industry averages, reflecting high growth expectations. Insider selling totaled $683.3 million over the past year. Rocket Lab has a GF Score of 77/100, indicating strong financial health but weak profitability.

$RKLBMed

Rocket Lab pushes Neutron rocket's debut flight to 2027, shares fall

Rocket Lab announced a delay in the debut flight of its Neutron rocket to 2027, pushing back from the previously targeted fourth quarter of 2026. The news caused the company's shares to drop about 6% in extended trading. Neutron is a reusable medium-lift rocket aimed at competing for larger commercial and national-security missions. Recently, Rocket Lab secured a multi-year launch agreement for 20 missions with Tokyo-based Synspective.

$RKLBHigh

Why is Rocket Lab stock tumbling today?

Rocket Lab (RKLB) stock dropped 7.2% in after-hours trading after delaying its Neutron rocket launch to 2027 due to manufacturing issues. The company also faces insider-selling pressure and a challenging macro environment with rising Fed rate hike bets. The stock is down over 60% from its 52-week high.

$RKLBHigh

Rocket Lab Stock Stumbles Despite Big Space Ambitions

Rocket Lab USA (RKLB) shares fell 8% during and after trading due to CEO Peter Beck's planned stock sale, SpaceX funding concerns, and a delay in the Neutron rocket launch to 2027. Despite record Q2 revenue of $234M and a strong backlog, investors worry about integration risks and profitability. Analysts maintain a Strong Buy rating with a $104.44 price target.